Company intelligence / Profile preview

Antiverse

Cardiff, Wales, United Kingdomantiverse.io ↗

Ownership: Private
Employees: ~16
Development stage: Preclinical

Overview

Antiverse has demonstrated the ability to identify therapeutic antibodies using its AI-driven drug discovery platform. The company claims it can deliver functional binders in as little as six months and has ongoing collaborations with major pharmaceutical companies. No published clinical results yet; focus remains on preclinical discovery and validation.

Therapeutic areas: OncologyOther
Modalities: monoclonal antibodies (mAbs)de novo antibody therapeutics
Industry: Biotech

Drug pipeline

1 asset

D13

Preclinical

Partnerships

Three top global pharmaceutical companies (names undisclosed)GlobalBio Inc. – collaboration for advancing cancer therapeutics using their technology/platform.

Beyond the preview

Go deeper on Antiverse.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antiverse.

Explore the full profile